Galectin Therapeutics Inc insider trading
Every open-market purchase and sale by Galectin Therapeutics Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Galectin Therapeutics Inc’s insiders pay?
From June 17, 2011 to December 23, 2025, 20 insiders reported 40 open-market purchases and 23 sales not made under a pre-set plan in Galectin Therapeutics Inc. Twelve months after each purchase was reported, the shares were −59.5% against the S&P 500 on average (median −60.4%), over 4 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −63.4% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 20, 2013 into $2,143 by November 2, 2026, −11.2% a year. It held shares 20% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $14,574 (+3.0% a year), and held throughout $52,733 (+13.7%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Freeman Kevin D | Director | 13 | — | — | 0 | — | December 23, 2025 |
| Czirr James C | Executive Chairman | 1 | — | — | 7 | −61.9% (3) | December 18, 2025 |
| 10x Capital Management, LLC | 10% owner | 0 | — | — | 5 | −44.5% (1) | December 4, 2025 |
| Uihlein Richard E | Director | 5 | −61.7% (1) | 0% | 0 | — | September 9, 2020 |
| Amelio Gilbert F | Director | 1 | — | — | 3 | — | January 19, 2021 |
| Eldred Kary | Director | 3 | −40.5% (1) | 0% | 0 | — | December 26, 2024 |
| Martin Rod D | Director | 1 | — | — | 2 | −79.5% (2) | January 14, 2014 |
| Rubin Marc | Director | 3 | −76.6% (1) | 0% | 0 | — | December 8, 2017 |
| Traber Peter G | President & CEO | 3 | — | — | 0 | — | June 1, 2015 |
| 10x Fund, L.P. | Director | 0 | — | — | 2 | — | October 19, 2021 |
| Callicutt Jack W | Chief Financial Officer | 1 | — | — | 1 | −56.8% (1) | June 3, 2019 |
| Greenberg Arthur | Director | 2 | −59.1% (1) | 0% | 0 | — | November 19, 2013 |
| Omenn Gilbert S | Director | 1 | — | — | 1 | −39.2% (1) | June 3, 2019 |
| Zordani Richard A. JR. | Director | 2 | — | — | 0 | — | July 29, 2022 |
| Lewis Joel | Director | 1 | — | — | 0 | — | June 3, 2019 |
| Mauldin John F | Director | 1 | — | — | 0 | — | April 26, 2012 |
| Mcgauley Thomas | Chief Financial Officer | 1 | — | — | 0 | — | May 25, 2012 |
| Prelack Steven | Director | 0 | — | — | 1 | −85.0% (1) | April 14, 2014 |
| Pressler Herman Paul | Director | 1 | — | — | 0 | — | April 26, 2012 |
| Zucconi Theodore Daniel | Director | 0 | — | — | 1 | — | April 18, 2018 |
When several insiders traded Galectin Therapeutics Inc
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Galectin Therapeutics Inc in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 2 selling crowds, −17.3%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| June 29, 2018 | 4 selling | −13.2% | −39.2% | −50.0% |
| October 31, 2013 | 3 selling | +20.5% | +4.7% | −65.1% |